ABCA3, ACD, AP3B1, AP3D1, BLOC1S3, BLOC1S6, COPA, CSF2RA, CTC1, DKC1, DTNBP1, ELMOD2, FAM111B, FARSB, FGF10, GRHL2, HPS1, HPS3, HPS4, HPS5, HPS6, ITGA, KIF5, LIG4, MARS1, MUC5B, NAF1, NHP2, NKX2-1, NOP10, PARN, POT1, RTEL1, SFTPA1, SFTPA2, SFTPB, SFTPC, SFTPD, SLC34A2, STING1, TERC, TERT, TINF2, USB1, WRAP53, ZCCHC8
Hermansky-Pudlak Syndrome & Pulmonary Fibrosis NGS Panel
Hermansky-Pudlak Syndrome & Pulmonary Fibrosis NGS Panel
The Hermansky-Pudlak Syndrome & Pulmonary Fibrosis NGS Panel is a 47-gene panel intended for patients with a diagnosis or clinical suspicion of an inherited pulmonary disorder.
Autoimmune interstitial lung\, joint\, and kidney disease, Choreoathetosis\, hypothyroidism\, and neonatal respiratory distress, Dubowitz syndrome, Dyskeratosis congenita, Ectodermal Dysplasia/Short Stature syndrome, Hereditary fibrosing poikiloderma with tendon contractures\, myopathy\, and pulmonary fibrosis, Hermansky-Pudlak syndrome, Idiopathic pulmonary fibrosis, Interstitial lung and liver disease, Junctional epidermolysis bullosa, LIG4 syndrome, Neurodevelopmental disorder with brain\, liver\, and lung abnormalities, Niemann-Pick disease, Pediatric pulmonary alveolar proteinosis, Poikiloderma with neutropenia, Pulmonary fibrosis, Pulmonary surfactant metabolism dysfunction, Rothmund-Thomson syndrome, STING-associated vasculopathy with onset in infancy, Telomere-related pulmonary fibrosis and/or bone marrow failure
Clinical Information
Primary features include hypopigmentation of the hair, skin, and eyes, nystagmus, and associated visual impairment. In addition to the pigmentation findings, individuals with Hermanksy-Pudlak may also have prolonged bleeding times and easy bruising, kidney failure, and bowel disorders. Pulmonary fibrosis caused by scarring of lung tissue may also be present, and symptoms include shortness of breath and a dry cough leading to death from respiratory failure within a few years without effective treatment.
Technical Information
This panel is performed by Next Generation Sequencing and covers the coding regions of the listed genes and the flanking intronic sequences. Promoter, 3′ untranslated sequences, and deep intronic sequences are also covered, but only known disease-causing variants in these regions will be reported. Variants identified on the panel are confirmed with Sanger sequencing if they do not meet certain quality thresholds.
Large deletions and duplications (CNVs) affecting the genes of the panel can be detected; however, due to defined settings in the analysis software, CNVs smaller than 2-kb may not be identified (for example, some small exonic level copy number changes may not be identified). Please note that certain types of genetic alterations including trinucleotide repeat expansions, methylation abnormalities, and balanced rearrangements (e.g., inversions, reciprocal translocations) may not be detected by the current analysis. Analysis of the MUC5B gene is limited to the c.-3133G>T promoter variant.
Specimen Requirements
Transport Instructions
Connect With Our Experts
Call 1-800-473-9411 to speak with our team of laboratory genetic counselors for questions or additional information.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC
